Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC37A4 | O43826 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL2948902 | 0.98 | SLC37A4 (0.48) | SLC37A4EGFRPIM1ELANEMEN1 | |
| Anthraquinone SCHEMBL2946623 | 0.90 | SLC37A4 (0.45) | SLC37A4MEN1KMT2A | |
| SCHEMBL2955955 | 0.90 | SLC37A4 (0.45) | SLC37A4MEN1KMT2A | |
| SCHEMBL2958068 | 0.84 | ELANE (0.49) | SLC37A4EGFRPIM1ELANEMEN1 | |
| SCHEMBL4463478 | 0.83 | SLC37A4 (0.42) | SLC37A4EGFRPIM1ELANEMEN1 | |
| SCHEMBL2955820 | 0.77 | SLC37A4 (0.46) | SLC37A4ELANEMEN1KMT2A | |
| SCHEMBL2947006 | 0.76 | SLC37A4 (0.48) | SLC37A4ELANEMEN1KMT2A | |
| SCHEMBL2957671 | 0.74 | MAPT (0.44) | SLC37A4MEN1KMT2A | |
| SCHEMBL4463498 | 0.73 | RAB9A (0.40) | SLC37A4MEN1KMT2A | |
| SCHEMBL9878218 | 0.72 | EGFR (0.54) | EGFRPIM1ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763740-B2 | Method for the production of mumbaistatin derivatives | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20090156836-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156836-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | MMAB, MLYCD, HMBS | SLC37A4 4052/4885EGFR 2996/4885PIM1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.